San­doz an­tic­i­pates ad­di­tion­al $3B in po­ten­tial net sales over five years in pipeline ex­pan­sion

San­doz to­day gave in­sight in­to its over­all strat­e­gy once it be­comes an in­de­pen­dent com­pa­ny lat­er this year, in­clud­ing plans to ex­pand its work in biosim­i­lars and build rev­enue af­ter claim­ing $9.1 bil­lion in sales last year.

The gener­ics mak­er and cur­rent No­var­tis di­vi­sion host­ed a cap­i­tal mar­kets day in New York City on Thurs­day — the first of two such days, with the sec­ond one planned for Lon­don next week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER